News

Santé log14h
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS
WEST PALM BEACH, FLORIDA, June 30, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle ...
Santé log14h
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...
Santé log14h
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted ...
Santé log14h
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies ...
Santé log14h
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...
Santé log14h
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby ® and ongoing late-stage pipeline programs Transaction monetizes ...
Santé log14h
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational ...
Santé log14h
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and ...
Santé log14h
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
AB Science SA (Euronext - FR0010557264 - AB) today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt (for a ...
Santé log14h
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation ...
Santé log8h
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs ...
Santé log8h
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
About the Phase 1 study The Phase 1 clinical pharmacology study is a double-blind, randomized, placebo-controlled, two-part trial to assess the safety, tolerability, and immunogenicity of up to 3 ...